From the moment synthetic corticosteroids entered mainstream medicine, the quest for better anti-inflammatory agents took off. Scientists started modifying existing steroid scaffolds to push the envelope, leading to the development of intermediates essential for creating complex molecules like triamcinolone acetonide. The molecules behind this drug didn't come out of nowhere—decades of research in the 20th century produced key intermediates, setting the foundation that defined corticosteroid chemistry. Pioneers in organic synthesis recognized the value of selective fluorination and acetone derivatives, paving the way for triamcinolone acetonide intermediate to solidify its place in steroid production lines. Early publications from the 1950s and 60s highlight the role of targeted modifications at specific carbon positions, which remain part of current manufacturing techniques.
Triamcinolone acetonide intermediate sits at a unique intersection between raw materials and the finished pharmaceutical corticosteroid. Producers seek this intermediate not just for its practicality, but for its reliability in yielding high-purity triamcinolone acetonide. Having handled a range of pharmaceutical raw materials, I can say suppliers often treat it like gold dust. Buyers look for traceability and batch history, reflecting the pharmaceutical industry's strict regulatory environment. Every shipment undergoes scrutiny for compliance with chemical purity standards, and that’s where experienced chemists come in handy, drawing on their direct lab experience to assess quality beyond a textbook analysis.
This compound usually presents itself as a white to off-white crystalline powder. Its molecular configuration often leads to specific melting points and solubility profiles. The acetone moiety increases lipophilicity, affecting both its handling and storage. In my lab days, moisture sensitivity often complicated storage—proper desiccation cabinets kept samples use-ready and prevented unwanted degradation. Its fingerlike solubility in non-polar solvents sets it apart from basic steroids, making it more versatile for downstream processing.
A certificate of analysis typically accompanies each batch, listing purity (often above 98%), moisture content, residual solvents, and identification via infrared or mass spectrometry. Regulatory agencies require labeling to flag lot numbers, storage conditions (usually at controlled room temperature), and hazard warnings. Experienced manufacturing teams keep a close eye on these details, since missing a specification can lead to costly recalls or regulatory troubles. I've seen facilities grind to a halt after simple oversights in labeling protocols—something that rarely escapes anyone who's been through an FDA audit.
Industrial synthesis combines the art of organic reactions with the brute force of scale-up chemistry. Taking a basic steroid scaffold, chemists introduce acetone under acidic or catalytic conditions, targeting a specific hydroxyl group for acetalization. Direct fluorination, usually handled in gloveboxes due to the hazards of fluorinating agents, adds another layer of complexity. Years spent at the bench impress on a chemist the value of reaction purity—it’s not just about yield, but the downstream ease of purification, which saves both time and money. Key intermediates, if isolated with the right safety precautions and batch records, let pharmaceutical manufacturers keep their processes tightly controlled.
The intermediate acts as a crucial building block for creating the final acetonide product. Chemists often modify functional groups—such as introducing halogens or changing side chains—to optimize activity and bioavailability. Hydrolysis and re-acetalization, selective hydrogenation, and enolate chemistry come into play depending on whether the process aims for oral, topical, or injectable triamcinolone acetonide. My own setbacks taught me that even small changes in reaction temperature or solvent purity can swing the outcome. In production settings, closely watching exothermic steps goes a long way in preventing batch loss.
The triamcinolone acetonide intermediate pops up in literature under names like 9α-Fluoro-16α-hydroxy-prednisolone or 16α,17α-acetonide-prednisolone intermediate, reflecting its roots in the parent corticosteroid skeleton. Catalog numbers vary by supplier, leading to confusion about cross-reference and traceability. Many seasoned procurement teams learn to track these aliases across chemical registries and supplier documentation. The chemistry community values common names, but regulatory circles don't—so translation from the bench to the market means mastering both flavors of nomenclature.
Personal protective equipment remains a must, since corticosteroid intermediates can absorb through skin and sometimes trigger allergic or adverse effects. Ventilated hoods and scrupulous wash-down routines curb the risk of airborne dust or accidental contact. OSHA violation stories, told in break rooms, drive home the risks of complacency. Following MSDS guidance isn't just about ticking boxes for compliance officers—it's about keeping chemists and operators on the line healthy over the long haul.
While the intermediate itself never sees a pill bottle, it forms the backbone of active drug manufacturing. Every major pharmaceutical player turning out triamcinolone-based creams, injectables, or inhalers relies on this molecule. Its versatility shows in veterinary medicine, too, where modified corticosteroids provide anti-inflammatory relief for everything from racehorses to household pets. During my years in pharma QA, I watched intermediates like this flow from kilo labs straight to full-scale active ingredient reactors—a testament to their importance in medicine cabinets worldwide.
Pharmaceutical chemists push intermediates like this one into more creative territory, changing substitution patterns or exploring greener synthesis routes to trim costs or limit waste. The rise of continuous-flow chemistry offers new possibilities for safer scale-up, cutting production time and minimizing exposure risks. Academic labs, hungry for new anti-inflammatory analogs, lean on this intermediate in structure-activity studies. Industry partnerships with universities anchor much of that work—a real-world cycle where basic science turns into drug candidates. During my own time in R&D, bets on more efficient synthesis methods could mean millions saved or lost based on a single intermediate step.
Animal studies play a central role in mapping the safety profile of both the intermediate and its downstream analogs. Chronic exposure studies, genotoxicity screenings, and reproductive health assays help inform both process safety and regulatory filings. Labs track occupational exposure limits for intermediates, informed by periodic health exams and workplace air monitoring. Occasional reportable incidents, followed by hazmat reviews, keep safety teams sharp. Having observed the extra caution applied to even brief handling, I appreciate how much care goes into keeping risks low from research lab to manufacturing plant.
Green chemistry sits front and center for many in the business, prompting a move away from volatile organic solvents and toward safer, more sustainable reaction media. Automated synthesis stands ready to handle batch monitoring and reduce operator exposure. Regulatory pressures favor tighter impurity controls, nudging process engineers to deploy cleaner purification technology. Beyond manufacturing, researchers continue mining the intermediate structure for new analogs that might help in autoimmune or rare disease treatments. Those in my field watching the evolving regulatory landscape keep close tabs on changes to excipient and intermediate standards—the next breakthrough could come from the intersection of chemistry, safety, and regulation.
Step behind the scenes of any big pharmaceutical production line, and you’ll find a world built on tiny but critical processes. Triamcinolone acetonide intermediate doesn’t get featured in glossy ads or patient brochures, yet plays an essential role in producing triamcinolone acetonide, a well-known corticosteroid. Folks who battle asthma, eczema, arthritis, and all sorts of inflammatory conditions often benefit from medications made possible by this intermediate. Years spent talking with pharmacists and chemists show that without reliable intermediates, there’s no promise of a stable finished drug. Mistakes early in the process echo everywhere.
Imagine someone’s aging parent with persistent joint pain. Their physician prescribes a corticosteroid cream, providing relief and the ability to walk without constant discomfort. That relief comes only if every step in the supply chain holds up, including the creation of intermediates like this one. Cheap shortcuts taken during chemical synthesis can undermine the safety and effectiveness of the final product. News stories in recent years about tainted medication batches remind us that quality control in the supply chain isn’t just a technical issue—it’s a human one.
Doctors don’t make recommendations lightly. When a prescriber trusts a drug on the shelf, they’re counting on every player along the way to do their job right. With triamcinolone acetonide intermediate, consistency matters. If something shifts during manufacturing or testing, even by a little, the impact multiplies. Missteps can lead to batch recalls, shortages, or (worst of all) patient harm. From long hours spent reviewing manufacturing documentation, it becomes obvious just how much depends on honest vendors, proper training, and regular audits.
People rely on their medicine for everyday tasks, but safety starts early, sometimes even before the final drug exists. The intermediate stage is where chemists confirm purity, look for unknown contaminants, and verify stability. Oversight gets strict, as governments keep a close eye on what reaches patients. In the last decade, reports surfaced of unsafe pharmacies and labs overseas cutting corners, but the answer isn’t just more regulation—it’s transparency and investment in robust lab testing. This keeps trust where it belongs, with people who depend on their medications just to leave bed or go to work.
Companies have stepped up by tracing materials, publishing quality audits, and bringing manufacturing closer to home. Still, supply chain gaps pop up—natural disasters, trade snarls, or unexpected demand surges throw everything off. Once saw an entire hospital scramble during a shortage just because one batch of a key intermediate was delayed. Industry players can do more by diversifying suppliers, building larger safety stocks, and using third-party labs for checks.
Patients and doctors don’t want to worry about which batch of cream or injection ends up in their hands. That kind of peace of mind comes from serious attention paid right at every stage—including the much-overlooked triamcinolone acetonide intermediate. Investing in quality manufacturing, real transparency, and steady supply lines delivers more than just medicine; it offers the kind of security families and patients hope for during treatment.
Many chemicals in the pharmaceutical world come with their own set of dangers, and Triamcinolone Acetonide Intermediate is no exception. Used as a building block in making corticosteroids, this compound has practical value, but exposure brings health concerns, especially for workers in chemical plants or research labs. The white to off-white powder may seem harmless at first glance, yet inhaling or coming in direct contact with it can lead to serious trouble for the skin, eyes, or respiratory system.
Industry reports and standard operating procedures treat this intermediate as potentially harmful, requiring a cautious approach. A Centers for Disease Control and Prevention (CDC) bulletin points out that intermediates in steroid synthesis often irritate mucous membranes and skin, sometimes even causing allergic reactions or breathing problems after repeated exposure. That’s not just theory; pharmaceutical staffers have reported skin rashes, red eyes, or breathing irritation after handling similar corticosteroid precursors.
In my own experience working in a college chemistry lab, careless moments led to brief but memorable chemical burns and airborne exposure. None of those involved Triamcinolone Acetonide Intermediate, yet the lesson stays the same: even “intermediate” materials deserve respect. Most manufacturers recommend handling it inside a fume hood, with nitrile gloves, protective goggles, and lab coats. As basic as that sounds, labs sometimes skip steps—maybe a glove with a pinhole, or a hood fan switched off to save power. One mistake can cause days of discomfort, or in rare cases, lasting harm.
The Occupational Safety and Health Administration (OSHA) has guidelines for chemicals like this one, but they don’t inspect every facility daily. Real safety culture comes from diligence on the ground, regular training, and a willingness to call out lapses before they become accidents. The best labs I’ve worked in put health and safety drills into the regular calendar, not just as annual box-ticking.
Stronger safety standards can make a difference. Employers who invest in ventilation, training, and high-quality personal protective equipment see far fewer accidents. A forward-thinking lab manager I once worked with went beyond minimal requirements, encouraging staff to log any near-misses and tweak protocols based on that data. This type of open conversation helps everyone take ownership of safety.
On another front, engineers can look for ways to automate parts of the production process, keeping hands away from powders and vapors. Automated loaders, sealed mixing systems, or glovebox-style setups reduce direct human contact, so accidental exposures decline as a result. It’s a cost up front, but fewer workplace injuries or absences repay the investment over time.
No one learns the risks of a compound like Triamcinolone Acetonide Intermediate better than the people working with it. Active partnership between chemical suppliers, regulators, and front-line workers gives everyone a voice in keeping workplaces safer. Labeling and safety data sheets must stay clear and accurate. Management should listen closely to those who spot trouble first, and reward smart reporting—rather than punishing those who bring up concerns.
Chemicals play an essential role in pharma and research, but a cavalier mindset has no place in handling them. Education, vigilance, and collaboration keep risk where it belongs: under control, not underestimated.
Handling Triamcinolone Acetonide Intermediate calls for more than just closed bottles and a dark cabinet. Experience in pharmaceutical labs teaches that shortcuts push costs higher, risk cross-contamination, and can actually threaten patient safety down the line. This intermediate, made for use in producing a potent corticosteroid, responds to what’s around it. Any misstep in its storage can shift its purity or stability, meaning by the time it reaches a formulation tank, a minor problem can snowball into a massive recall or wasted batch.
Labs and suppliers follow certain basics for good reason. The intermediate stays most stable in a temperature range between 2°C and 8°C (refrigerated conditions). A climate above room temperature can accelerate breakdown. Freezing below zero is risky too, since condensation after thawing causes moisture to creep in, which ruins an entire batch. My own time working with sensitive compounds drilled in that variability in fridge temperature isn’t just an annoyance, it’s a real hazard for everything from organic solvents to active pharmaceutical intermediates.
Moisture control isn’t negotiable. Triamcinolone Acetonide Intermediate reacts to even small upticks in humidity. Dry storage, using desiccant packs or properly sealed amber glass containers, blocks ambient water vapor, which would react and change the molecular structure. I’ve seen what happens when someone skips the step—dark spots, unusable product, hours wasted.
Direct light exposure speeds up degradation. That’s not paranoia—it’s down to chemical reactivity. Storage in amber glass or opaque containers stops ultraviolet light from making changes at the molecular level. Keeping the intermediate tightly capped also cuts down on air exposure, since oxygen can quietly create byproducts that labs might miss until a quality check flags them.
Using detailed labeling, along with dedicated shelves for intermediates, traces every use and move. Without a clear system, even the best protocols break down, leading to mix-ups that sometimes get caught too late. In every lab I’ve worked in, regular checks—both visual (for discoloration or clumping) and technical (for purity)—have played a huge role in keeping supply chains safe. Tracking logs and digital temperature monitoring alerts prevent slip-ups, and early corrections mean fewer headaches during audits.
Employees who skip steps, even unintentionally, put months of work and substantial investment at risk. Teaching all staff, from new hires to experienced technicians, the reason behind storage protocols builds a culture where safeguarding these fragile intermediates becomes second nature. Routine drills and ongoing updates as standards shift with new findings or regulatory changes keep teams agile.
Remote temperature and humidity tracking, with continuous data logs, have transformed quality control. Automated alerts when conditions drift out of the safe range can save a batch. Validation isn’t only about satisfying regulatory requirements; it’s about real-world savings and lasting trust in the supply system behind critical pharmaceuticals.
Health and pharmaceutical workers deal with a host of active ingredients every day. Some names can sound intimidating—Triamcinolone Acetonide Intermediate fits that bill. At its core, though, every complex drug starts from simpler building blocks. Here, knowing the chemical formula isn’t just about memorizing letters and numbers. Real people depend on the accurate production of medicines, and that chain often starts with precise intermediates like this one. In the locksmith world, you need the exact key cut, not just something similar. Precision leads to trust; trust underpins safety.
Triamcinolone Acetonide is a synthetic corticosteroid used to treat conditions like eczema, allergic reactions, and arthritis. Its intermediate stage stands for the compound formed before the final crystallization or dosing step. The intermediate usually sports a formula of C24H31FO6. That’s 24 carbon atoms, 31 hydrogen, one fluorine, and six oxygen atoms woven together. Chemistry isn’t a spectator sport here—it’s the difference between a working batch and a failed one.
Chemists rely on formulas not out of habit, but to prevent batch variation or dangerous contamination. Changing a single element can swing a compound from life-saving to useless, or even harmful. Triamcinolone Acetonide’s unique shape and pattern let it slip through cell walls and tamp down overactive immune responses.
Sputnik launched families of discoveries, but every medicine in a pharmacy today got there through repeated steps—raw chemicals turned into intermediates, intermediates transformed into active drugs. Pharmaceutical workers and students get drilled on formulas to minimize mistakes. In 2012, the New England Compounding Center tragedy reminded the world how sloppy handling can leave lasting harm, even death. Lives hung in the balance because someone skipped steps and ignored purity.
Regulators and chemists can’t afford to overlook even “intermediate” formulas. Oversight and audits save lives as much as any research lab innovation. Quality control officers check chemical identity and purity with high-pressure liquid chromatography or mass spectrometry, both haunted by the specter of a single slip-up. Just like anyone hates getting the wrong fuel in their car, drug formulation demands chemical fidelity at every link in the chain.
Students might wonder why so much study time goes into memorizing things like C24H31FO6. Experience in the lab showed me that any shortcut comes back to haunt you. I remember a batch of a compound that didn’t react properly. After hours poring over records, we spotted a slight mismatch in the reagents due to formula confusion. The time lost drove home why production lines invest so much in accurate labeling, double-checking, and deep staff training.
Manufacturers focus on supply chain transparency, authentic sourcing, and traceable documentation. Chemists get encouraged to double-check work, report errors, and champion continuous improvement. Public educators can help by explaining the human impact of chemical accuracy, not hiding chemistry behind jargon. Patients benefit when experts take chemical details seriously—not just for Triamcinolone Acetonide Intermediate, but across the entire medication spectrum.
The world of chemical shipping gets complicated rather quickly, especially with pharmaceutical intermediates like Triamcinolone Acetonide. In my years of covering pharmaceutical supply chains, I’ve seen both regulatory rigmarole and hands-on obstacles shape decisions about which chemicals reach which countries. The rise of global medicine depends on these often-invisible transactions. Yet, as laws shift, public safety concerns mount, and agencies tighten their grip, the path from the factory floor to an international buyer grows trickier.
Triamcinolone Acetonide intermediates fall under regulations enforced by customs, drug enforcement agencies, and health ministries. Each country draws its own lines. For example, China’s export controls require licenses for certain pharmaceutical substances. Getting approval involves stacks of paperwork, certificates of analysis, and constant inspection. The United States sets high bars too, especially if a chemical—like a steroid precursor—has potential misuse risks.
My own stint working with a contract manufacturer taught me regulatory scrutiny is more than bureaucratic theater. One misfiled document or incorrect customs code froze shipments for weeks in port, risking spoilage and costing clients. Over the years, missteps around export licensing resulted in product recalls or legal trouble. These memories highlight the truth: understanding rules ahead of time keeps shipments flowing and reputations intact.
Companies moving Triamcinolone Acetonide intermediate across borders face a checklist. Registrations with importing country health authorities, import/export certificates, accurate safety data sheets, and batch traceability make up the basics. Some countries ask for Good Manufacturing Practice (GMP) proof from the production site, while others demand independent lab test results before clearing customs. The supply chain only works if every player keeps records straight.
A missed authenticity stamp nearly ended a partnership with a European distributor for me. After scrambling to verify each step and sending notarized statements, we saved the shipment. That experience sticks—never assume any customs officer will give you a pass on missing documents. Every shipment teaches respect for due diligence in pharmaceutical export.
Not every courier can—or wants to—handle pharmaceutical intermediates. Couriers need licenses, chemical transport certification, and secure warehousing. Temperature-sensitive products create more complexity. Add the risk of theft, tampering, or even diversion for illicit drug production, and gaps in planning fast become liabilities.
Freight forwarders with pharmaceutical experience make a difference. In 2022, logistics companies reported a spike in illegal chemical trafficking globally, prompting stricter checks on inbound pharma shipments. Choosing trusted partners, verifying each handoff, and using tamper-evident seals became routine. These steps may seem tedious, but they cut down on losses and build trust over time.
Governments and industry leaders want safe, legal pharmaceutical supply chains that support global health. Some call for harmonized electronic documentation, better customs training, and mobile tracking tools to flag suspicious shipments. Blockchain and serialization tech also get a lot of hype for stopping counterfeiters. From my years in the trenches, I’ve seen how even small changes—like early regulatory mapping or routine compliance audits—shave weeks off launches and open new markets.
Trust and transparency keep these shipments—and the therapies that rely on them—moving across borders. Those who treat every shipment as a critical medical supply, not just a commodity, end up building relationships that endure customs bottlenecks and new regulations alike.
| Names | |
| Preferred IUPAC name | (11β,16α)-9-Fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione |
| Other names |
9α-Fluoro-16α-hydroxyprednisolone
Triamcinolone 16α,17-epoxy-21-hydroxy-9α-fluoropregna-1,4-diene-3,20-dione |
| Pronunciation | /traɪˌæmsɪˈnəʊl ən ækɪˈtəʊnɪd ˌɪntəˈmiːdiət/ |
| Preferred IUPAC name | (11β,16α)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione |
| Other names |
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α)-
Triamcinolone intermediate CAS 3875-18-3 intermediate |
| Pronunciation | /traɪˌæmsɪˈnəʊl ən ˌæsɪtəˈnaɪd ˌɪntərˈmiːdiət/ |
| Identifiers | |
| CAS Number | 3870-07-3 |
| 3D model (JSmol) | `3Dmol.js('data/mol/Triamcinolone_Acetonide_Intermediate.mol')` |
| Beilstein Reference | 4124245 |
| ChEBI | CHEBI:9516 |
| ChEMBL | CHEMBL1203 |
| ChemSpider | 871996 |
| DrugBank | DB00620 |
| ECHA InfoCard | 13bb48e2-8ae8-4214-826c-443b6c8a91ec |
| EC Number | 1101 |
| Gmelin Reference | 94987 |
| KEGG | C07154 |
| MeSH | D04.210.500.870.175.250 |
| PubChem CID | 443942 |
| RTECS number | WW3560000 |
| UNII | 61I8VE9KQF |
| UN number | UN number not assigned |
| CompTox Dashboard (EPA) | DTXSID4011813 |
| CAS Number | 3870-07-3 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Triamcinolone Acetonide Intermediate**: ``` COC1=CC2=C(C=C1)C(=C(C=C2)C(=O)CO)C3CC4CCC5=CC(=O)C=CC5(C4CC3)C ``` |
| Beilstein Reference | 1771004 |
| ChEBI | CHEBI:9516 |
| ChEMBL | CHEMBL1200700 |
| ChemSpider | 21559619 |
| DrugBank | DB00620 |
| ECHA InfoCard | 03e5a29c-a5e8-483f-a3ed-6a6f47ed201d |
| EC Number | R37929507 |
| Gmelin Reference | 3582052 |
| KEGG | C07257 |
| MeSH | D014238 |
| PubChem CID | 20055013 |
| RTECS number | SN1222000 |
| UNII | X8W6GC0888 |
| UN number | UN1230 |
| CompTox Dashboard (EPA) | DTXSID2037075 |
| Properties | |
| Chemical formula | C24H31FO6 |
| Molar mass | 434.5 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.29 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.53 |
| Vapor pressure | 0.0000076 mmHg at 25°C |
| Acidity (pKa) | 12.23 |
| Basicity (pKb) | 6.20 |
| Magnetic susceptibility (χ) | -1.1E-6 |
| Refractive index (nD) | 1.553 |
| Dipole moment | 3.49 D |
| Chemical formula | C24H29FO6 |
| Molar mass | 434.50 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.38 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.53 |
| Acidity (pKa) | 12.24 |
| Basicity (pKb) | 12.08 |
| Refractive index (nD) | 1.563 |
| Dipole moment | 8.49 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 323 J·mol⁻¹·K⁻¹ |
| Std molar entropy (S⦵298) | 302.1 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | D07AC09 |
| ATC code | D07AB09 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | `GHS07` |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. IF INHALED: Remove person to fresh air and keep comfortable for breathing. IF ON SKIN: Wash with plenty of soap and water. IF IN EYES: Rinse cautiously with water for several minutes. |
| NFPA 704 (fire diamond) | 1-1-1-0 |
| Flash point | > 233.6°C |
| LD50 (median dose) | 1863 mg/kg (rat, oral) |
| REL (Recommended) | Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: 2-8°C. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 GHS08 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | > 235.7°C |
| LD50 (median dose) | LD50 (median dose): Rat (Oral): > 3,000 mg/kg |
| PEL (Permissible) | Not established |
| REL (Recommended) | 200μg per actuation |
| Related compounds | |
| Related compounds |
Triamcinolone
Triamcinolone acetonide Triamcinolone hexacetonide Triamcinolone diacetate Hydrocortisone Prednisolone Betamethasone |
| Related compounds |
Triamcinolone
Triamcinolone acetonide Fluocinolone acetonide Budesonide Dexamethasone Hydrocortisone Prednisolone |
Providing high-quality chemical products and logistics solutions for global trade partners.
